<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="editorial" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1474918</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1474918</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: The pharmacological modulation of angiogenesis</article-title>
<alt-title alt-title-type="left-running-head">Pessolano et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1474918">10.3389/fphar.2024.1474918</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Pessolano</surname>
<given-names>Emanuela</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2532128/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Belvedere</surname>
<given-names>Raffaella</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1922838/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Spampinato</surname>
<given-names>Simona Federica</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/201649/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pharmaceutical Sciences, Universit&#xE0; del Piemonte Orientale</institution>, <addr-line>Novara</addr-line>, <country>Italy</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Pharmacy, University of Salerno</institution>, <addr-line>Fisciano</addr-line>, <addr-line>Salerno</addr-line>, <country>Italy</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Scienza e Tecnologia del Farmaco, University of Turin</institution>, <addr-line>Turin</addr-line>, <country>Italy</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited and reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/16703/overview">Filippo Drago</ext-link>, University of Catania, Italy</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Emanuela Pessolano, <email>emanuela.pessolano@uniupo.it</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>08</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1474918</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>08</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>08</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Pessolano, Belvedere and Spampinato.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Pessolano, Belvedere and Spampinato</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front. Pharmacol." xlink:href="https://www.frontiersin.org/researchtopic/62038" ext-link-type="uri">Editorial on the Research Topic <article-title>The pharmacological modulation of angiogenesis</article-title> </related-article>
<kwd-group>
<kwd>angiogenesis</kwd>
<kwd>tumor vasculature</kwd>
<kwd>diabetic retinopathy</kwd>
<kwd>corneal neovascularisation</kwd>
<kwd>pharmacological modulation</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Experimental Pharmacology and Drug Discovery</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>This editorial aims to provide an overview of the complex process of angiogenesis and its implications for human health. Angiogenesis is a complex process with far-reaching implications for human health. Its dysregulation can contribute to a myriad of diseases, including cancer, diabetic retinopathy, and impaired wound repair (<xref ref-type="bibr" rid="B2">Pessolano et al., 2018</xref>; <xref ref-type="bibr" rid="B3">Pessolano et al., 2021</xref>; <xref ref-type="bibr" rid="B1">Belvedere et al., 2022</xref>). <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2022.921189">Huang et al.</ext-link> demonstrated melatonin&#x2019;s efficacy in promoting angiogenesis, suggesting a promising avenue for reconstructive surgery. Indeed, in his work, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1384721">Ribatti</ext-link>&#x2019;s points the attention on tumor vasculature, revealing critical differences between healthy and cancerous vessels, offering targets for anti-cancer therapies. Finally, the importance of the pharmacological modulation of angiogenesis in pathological conditions is explored. Ocular neovascularization represents an important Research Topic in the loss of vision. The anti-angiogenic and antioxidant effects of axitinib are analysed and suggested as potential treatment for diabetic retinopathy by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1415846">Lazzara et al.</ext-link>
</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1411513">Deng et al.</ext-link> instead focuses on the ability of LSD-1 in controlling corneal neovascularization, identifying a potential therapeutic target. These studies collectively underscore the multifaceted nature of angiogenesis and its potential as a therapeutic target across various diseases.</p>
</body>
<back>
<sec id="s1">
<title>Author contributions</title>
<p>EP: Writing&#x2013;original draft, Writing&#x2013;review and editing. RB: Writing&#x2013;original draft, Writing&#x2013;review and editing. SS: Writing&#x2013;original draft, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s2">
<title>Funding</title>
<p>The authors declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s3">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec sec-type="disclaimer" id="s4">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belvedere</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Novizio</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Morello</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Petrella</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The combination of mesoglycan and VEGF promotes skin wound repair by enhancing the activation of endothelial cells and fibroblasts and their cross-talk</article-title>. <source>Sci. Rep.</source> <volume>12</volume> (<issue>1</issue>), <fpage>11041</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-15227-1</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pessolano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Belvedere</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bizzarro</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marco</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Porta</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Annexin A1 may induce pancreatic cancer progression as a key player of extracellular vesicles effects as evidenced in the <italic>in vitro</italic> MIA PaCa-2 model system</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume> (<issue>12</issue>), <fpage>3878</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19123878</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pessolano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Belvedere</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Novizio</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Filippelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Perretti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Whiteford</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Mesoglycan connects Syndecan-4 and VEGFR2 through Annexin A1 and formyl peptide receptors to promote angiogenesis <italic>in vitro</italic>
</article-title>. <source>FEBS J.</source> <volume>288</volume> (<issue>22</issue>), <fpage>6428</fpage>&#x2013;<lpage>6446</lpage>. <pub-id pub-id-type="doi">10.1111/febs.16043</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>